Skip to content
IPO

AstraZeneca shares climb after earnings beat estimates as cancer drug portfolio drives strong growth

N
Livemint Markets
Jul 27, 2026 · 10:48 PM 1 min reading time
AstraZeneca shares climb after earnings beat estimates as cancer drug portfolio drives strong growth
Adjusted earnings per share, excluding certain items, climbed 21% to $2.63 in the latest quarter, comfortably surpassing analysts' expectations
Read full original report at Livemint Markets Visit Source
Related Stories
Home IPOs GMP News Toolkit